Keyword: Moderna Therapeutics
On the heels of a $500M round, Moderna picked up another $125 million as it expands its cancer vaccine partnership with Merck.
Jamie Macdonald succeeds Joseph von Rickenbach as Parexel CEO, Roche promotes William Pao to replace John Reed as pRED head, Moderna loses vaccines head.
The huge series G round equips Moderna to gather more data on its pipeline of mRNA candidates ahead of its long-anticipated IPO.
Biogen executive Kress jumped to Syntimmune, Mendlein will guide Moderna's strategy and former FDA CIO Perakslis joined Roivant's Datavant.
The round positions BioNTech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by modalities including CAR-T cells.
Venture capital firm Flagship Pioneering has got a major $618 million in capital, the biggest in its 17-year history, topping its total to $2.3 billion.
The candidate is designed to induce production of relaxin, a hormone seen as a way to regulate the conditions that exacerbate heart failure.
Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.
A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.